11.27 USD
-0.01 (-0.09%)
11.27 USD
0 (0%)
Taking everything into account, OCUL scores 3 out of 10 in our fundamental rating. OCUL was compared to 192 industry peers in the Pharmaceuticals industry. OCUL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. OCUL is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year OCUL has reported negative net income.
- OCUL had a negative operating cash flow in the past year.
- OCUL had negative earnings in each of the past 5 years.
- OCUL had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- OCUL has a Return On Assets of -60.77%. This is in the lower half of the industry: OCUL underperforms 65.79% of its industry peers.
- Looking at the Return On Equity, with a value of -96.69%, OCUL is doing worse than 63.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -60.77% | ||
| ROE | -96.69% | ||
| ROIC | N/A |
ROA(3y)-40.62%
ROA(5y)-36.9%
ROE(3y)-116.88%
ROE(5y)-112.52%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 88.87%, OCUL belongs to the top of the industry, outperforming 90.53% of the companies in the same industry.
- OCUL's Gross Margin has improved in the last couple of years.
- OCUL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.87% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.47%
GM growth 5Y15.21%
2. Health
2.1 Basic Checks
- OCUL does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for OCUL has been increased compared to 1 year ago.
- OCUL has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, OCUL has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 4.82 indicates that OCUL is not in any danger for bankruptcy at the moment.
- The Altman-Z score of OCUL (4.82) is better than 73.16% of its industry peers.
- A Debt/Equity ratio of 0.27 indicates that OCUL is not too dependend on debt financing.
- With a Debt to Equity ratio value of 0.27, OCUL perfoms like the industry average, outperforming 41.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.82 |
ROIC/WACCN/A
WACC9.96%
2.3 Liquidity
- A Current Ratio of 7.85 indicates that OCUL has no problem at all paying its short term obligations.
- The Current ratio of OCUL (7.85) is better than 72.63% of its industry peers.
- OCUL has a Quick Ratio of 7.78. This indicates that OCUL is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of OCUL (7.78) is better than 73.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.85 | ||
| Quick Ratio | 7.78 |
3. Growth
3.1 Past
- OCUL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.88%.
- OCUL shows a decrease in Revenue. In the last year, the revenue decreased by -9.21%.
- Measured over the past years, OCUL shows a very strong growth in Revenue. The Revenue has been growing by 72.02% on average per year.
EPS 1Y (TTM)5.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-72.73%
Revenue 1Y (TTM)-9.21%
Revenue growth 3Y13.55%
Revenue growth 5Y72.02%
Sales Q2Q%-5.71%
3.2 Future
- OCUL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.24% yearly.
- OCUL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 55.79% yearly.
EPS Next Y-1.87%
EPS Next 2Y0.32%
EPS Next 3Y7.21%
EPS Next 5Y17.24%
Revenue Next Year-14.17%
Revenue Next 2Y-1.97%
Revenue Next 3Y20%
Revenue Next 5Y55.79%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for OCUL. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OCUL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.32%
EPS Next 3Y7.21%
5. Dividend
5.1 Amount
- No dividends for OCUL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
11.27
-0.01 (-0.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-04 2025-11-04/bmo
Earnings (Next)03-02 2026-03-02/amc
Inst Owners88.78%
Inst Owner Change0.34%
Ins Owners2.22%
Ins Owner Change3.61%
Market Cap2.40B
Revenue(TTM)55.78M
Net Income(TTM)-249.67M
Analysts86.32
Price Target24.82 (120.23%)
Short Float %5.12%
Short Ratio3.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-4.72%
Min EPS beat(2)-7.83%
Max EPS beat(2)-1.62%
EPS beat(4)0
Avg EPS beat(4)-12.26%
Min EPS beat(4)-26.63%
Max EPS beat(4)-1.62%
EPS beat(8)1
Avg EPS beat(8)-40.57%
EPS beat(12)4
Avg EPS beat(12)-25.42%
EPS beat(16)6
Avg EPS beat(16)-13.78%
Revenue beat(2)0
Avg Revenue beat(2)-1.48%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)-0.44%
Revenue beat(4)0
Avg Revenue beat(4)-10.82%
Min Revenue beat(4)-37.69%
Max Revenue beat(4)-0.44%
Revenue beat(8)1
Avg Revenue beat(8)-8.36%
Revenue beat(12)3
Avg Revenue beat(12)-6.11%
Revenue beat(16)3
Avg Revenue beat(16)-8.25%
PT rev (1m)8.96%
PT rev (3m)36.45%
EPS NQ rev (1m)-1.68%
EPS NQ rev (3m)4.51%
EPS NY rev (1m)-0.46%
EPS NY rev (3m)3.59%
Revenue NQ rev (1m)0.19%
Revenue NQ rev (3m)-0.9%
Revenue NY rev (1m)-0.28%
Revenue NY rev (3m)-0.54%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 43.04 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 9.3 | ||
| P/tB | 9.3 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.44
EYN/A
EPS(NY)-1.46
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS0.26
BVpS1.21
TBVpS1.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -60.77% | ||
| ROE | -96.69% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.87% | ||
| FCFM | N/A |
ROA(3y)-40.62%
ROA(5y)-36.9%
ROE(3y)-116.88%
ROE(5y)-112.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.47%
GM growth 5Y15.21%
F-Score2
Asset Turnover0.14
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 232.75% | ||
| Cap/Sales | 16.8% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.85 | ||
| Quick Ratio | 7.78 | ||
| Altman-Z | 4.82 |
F-Score2
WACC9.96%
ROIC/WACCN/A
Cap/Depr(3y)138.13%
Cap/Depr(5y)98.78%
Cap/Sales(3y)6.55%
Cap/Sales(5y)5.44%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-72.73%
EPS Next Y-1.87%
EPS Next 2Y0.32%
EPS Next 3Y7.21%
EPS Next 5Y17.24%
Revenue 1Y (TTM)-9.21%
Revenue growth 3Y13.55%
Revenue growth 5Y72.02%
Sales Q2Q%-5.71%
Revenue Next Year-14.17%
Revenue Next 2Y-1.97%
Revenue Next 3Y20%
Revenue Next 5Y55.79%
EBIT growth 1Y-77.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-59.56%
EBIT Next 3Y5.31%
EBIT Next 5Y19.4%
FCF growth 1Y-175.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-193.62%
OCF growth 3YN/A
OCF growth 5YN/A
OCULAR THERAPEUTIX INC / OCUL FAQ
What is the ChartMill fundamental rating of OCULAR THERAPEUTIX INC (OCUL) stock?
ChartMill assigns a fundamental rating of 3 / 10 to OCUL.
Can you provide the valuation status for OCULAR THERAPEUTIX INC?
ChartMill assigns a valuation rating of 0 / 10 to OCULAR THERAPEUTIX INC (OCUL). This can be considered as Overvalued.
How profitable is OCULAR THERAPEUTIX INC (OCUL) stock?
OCULAR THERAPEUTIX INC (OCUL) has a profitability rating of 1 / 10.
What is the earnings growth outlook for OCULAR THERAPEUTIX INC?
The Earnings per Share (EPS) of OCULAR THERAPEUTIX INC (OCUL) is expected to decline by -1.87% in the next year.